Patents Examined by Bao Q Li
  • Patent number: 10280199
    Abstract: Disclosed herein are embodiments of a method for collecting, extracting or eluting proteins and antigens from cells infected with coronavirus. The coronavirus may be a porcine coronavirus, such as porcine epidemic diarrhea virus (PEDV) or porcine delta coronavirus (PDCoV). Also disclosed are embodiments of a composition comprising the coronavirus proteins and antigens, and embodiments of a method of using such a composition. Applications for the composition include, but are not limited to, use in the preparation of antibodies against the proteins and antigens, use as reference markers for coronavirus proteins, and/or use in an immunogenic composition, such as in a vaccine composition.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: May 7, 2019
    Assignee: Phibro Animal Health Corporation
    Inventor: Byoung-Kwan Kim
  • Patent number: 10233484
    Abstract: Disclosed herein are methods and systems for detection of a microorganism of interest using an amplification assay. The methods and systems utilize the specificity of binding agents, such as antibodies, to rapidly detect low levels of a specific microorganism present in a sample. In certain embodiments, antibodies are bound to a large number of the available binding sites on a microorganism.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: March 19, 2019
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Dwight Lyman Anderson, Ben Barrett Hopkins, Jose S. Gil, Stephen Erickson, Ekaterina Kovacheva
  • Patent number: 10232003
    Abstract: The present invention relates to exogenous TAP inhibitor armed oncolytic viruses that replicate selectively in cancer cells, evade CD8+ cytolytic T-cells, and induce the immune system to recognize tumor cells. Preferred viruses of the invention have a heterologous gene that encodes a function that affects antigen presentation by inhibiting TAP. The viruses of the invention also comprise one or more heterologous genes encoding immunomodulatory polypeptides, prodrug converting enzymes, or matrix degrading enzymes. Compositions and therapeutic methods using the oncolytic viruses are also provided, including compositions and therapeutic methods for treating cancers, such as melanoma, head and neck cancer, ovarian cancer, breast cancer, glioblastoma, bladder cancer, prostate cancer, lung cancer, liver cancer, colorectal cancer, pancreatic cancer, and renal cancer.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: March 19, 2019
    Assignee: BeneVir Biopharm, Inc.
    Inventors: Matthew Mulvey, Steven Fuhrmann, Ram Aiyar
  • Patent number: 10221399
    Abstract: The invention provides compositions of matter comprising a cowpea chlorotic mottle virus capsid protein (CCMV CP) and a ribonucleic acid, as well as methods for using such compositions. In such compositions, the cowpea chlorotic mottle virus capsid protein envelops the ribonucleic acid so as to for a capsid that can inhibit the degradation of the ribonucleic acid (e.g. by RNAses). A method of delivering a ribonucleic acid into the cytoplasm of a mammalian cell is also provided. Typically, the method comprises the steps of combining the mammalian cell with a composition of matter described herein under conditions selected to allow the cowpea chlorotic mottle virus capsid to contact the mammalian cell and deliver the ribonucleic acid into the cytoplasm of a mammalian cell.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: March 5, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: William M. Gelbart, Charles M. Knobler, Rees F. Garmann, Odisse Azizgolshani, Ruben D. Cadena-Nava
  • Patent number: 10221218
    Abstract: Provided is a Titi Monkey Adenovirus (TMAdV) that can infect both human and non-human primates. Further provided are nucleic acid sequences, proteins, expression vectors and host cells, anti-TMAdV antibodies, vaccines, compositions, methods of detecting TMAdV, methods for assaying for anti-TMAdV compounds, and methods for treating or preventing a TMAdV infection.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: March 5, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Charles Chiu, Eunice Chen, Nicholas W. Lerche, Karen Lisa Bales
  • Patent number: 10209256
    Abstract: Lateral-flow assay and time-resolved fluorescence technologies provide a sensitive tool for detecting norovirus particles in a sample. A flow-through assay device employs norovirus and norovirus G2 antibodies. The lateral-flow assay includes a conjugate pad having conjugated probes. The conjugated probes are particles modified with a binding member that is configured to bind with a norovirus. The particles also have a fluorescent label. A general method of detecting the virus includes (i) preparing a sample with contaminants, (ii) processing the sample and depositing it onto the assay device, and (iii) measuring the fluorescence signal.
    Type: Grant
    Filed: November 27, 2014
    Date of Patent: February 19, 2019
    Assignee: Kimberly-Clark Worldwide, Inc.
    Inventors: Bao Trong Do, Jonathan Hofmekler, Cesar A. Morales, David W. Koenig, Yang Huang, Aimin He
  • Patent number: 10195267
    Abstract: In a first aspect, the present invention relates to the use of a TLR 9 agonist and/or a TLR 4 agonist in a prophylactic or therapeutic vaccine. According to the present vaccination strategy, the TLR 9 agonist and/or TLR 4 agonist is adapted or designed for use as a multiplying jump agent to enhance numbers and functionality of CD8 T cells in a prime-jump vaccination strategy for jump T cell expansion. In particular, the TLR 9 agonist and/or TLR 4 agonist is used as a component to be administered after priming of the individual to be vaccinated. The vaccination strategy is particularly useful against acute and chronic infections with intracellular pathogens or for anti-tumor vaccination. In another aspect, the present invention relates to a kit of part containing a prime agent and a multiplying jump agent according to the present invention.
    Type: Grant
    Filed: February 25, 2014
    Date of Patent: February 5, 2019
    Assignees: KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITÄT MÜNCHEN, TECH UNIVERSITÄT MÜNCHEN, HELMHOLTZ ZENTRUM MÜNCHEN—DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT
    Inventors: Percy Knolle, Li-Rung Huang, Mathias Heikenwälder, Ulrike Protzer
  • Patent number: 10188724
    Abstract: The present invention relates to methods and compositions for enhancing delivery of vaccine antigens to the mucosal epithelium, the composition comprising an antigen from an infectious agent fused with an Fc fragment of an immunoglobulin recognized by the neonatal receptors (FcRn). The composition is effective in eliciting a protective long-term memory T cell immune response against infection at a distant mucosal site.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: January 29, 2019
    Assignee: University of Maryland, College Park
    Inventors: Xiaoping Zhu, Lilin Ye, Li Lu
  • Patent number: 10192025
    Abstract: The present invention relates to the use of rotavirus particles for displaying a heterologous protein, alone or in complex with another molecule. The invention further relates to methods that employ these modified rotavirus particles to rapidly determine the structure of the heterologous protein or the complex using cryo-electron microscopy (cryo-EM). The invention also relates to a method of immunizing a patient, wherein said method comprises administering to the patient the modified rotavirus particles of the invention.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: January 29, 2019
    Assignee: Novartis AG
    Inventors: Philip R. Dormitzer, Nikolaus Grigorieff, Stephen Harrison, Junhua Pan, Ethan Settembre
  • Patent number: 10184004
    Abstract: Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRP? on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: January 22, 2019
    Assignees: The Board of Trustees of the Leland Stanford Junior University, The Regents of the University of California, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Kipp Andrew Weiskopf, Kim J. Hasenkrug, Cheryl A. Stoddart, Joseph McCrary McCune, Irving L. Weissman
  • Patent number: 10183069
    Abstract: The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings. Protective responses lasted for many weeks in a single-dose regimen in animal models. When a pathogen-derived antigen gene was inserted into the E1/E3-defective adenovirus genome, the antigen-induced protective immunity against the specific pathogen was elicited before the adenovirus-mediated protective response declined away, thus conferring rapid, prolonged, and seamless protection against pathogens. In addition to E1/E3-defective adenovirus, other bioengineered non-replicating vectors encoding pathogen-derived antigens may also be developed into a new generation of rapid and prolonged immunologic-therapeutic (RAPIT).
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: January 22, 2019
    Assignee: Altimmune Inc.
    Inventor: De-Chu C. Tang
  • Patent number: 10179805
    Abstract: Described herein is the generation of optimized H5N1 influenza HA polypeptides for eliciting a broadly reactive immune response to H5N1 influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on human and avian H5N1 isolates. Provided herein are optimized H5N1 HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides. Methods of eliciting an immune response against influenza virus in a subject are also provided by the present disclosure.
    Type: Grant
    Filed: December 27, 2016
    Date of Patent: January 15, 2019
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Ted M. Ross, Corey J. Crevar, Brendan M. Giles
  • Patent number: 10174084
    Abstract: The present invention relates to novel immunogenic polypeptides and their use in vaccine compositions. The invention also relates to nucleic acids, vectors and cells which express the polypeptides and the uses thereof. The polypeptides of the invention more specifically comprise an immunogenic domain and a cell membrane addressing domain which is derived from a B5R gene. The invention is particularly suited to produce vaccines for non-human animals, particularly for vaccinating swine against PCV2 infection.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: January 8, 2019
    Assignee: CEVA SANTE ANIMALE
    Inventor: Takanori Sato
  • Patent number: 10172930
    Abstract: Methods for purifying human Calciviruses are disclosed, including Noroviruses and Sapoviruses.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: January 8, 2019
    Assignee: TAKEDA VACCINES, INC.
    Inventors: Thomas S. Vedvick, Bryan Steadman, Charles Richardson, Thomas R. Foubert, Charles R. Petrie
  • Patent number: 10166281
    Abstract: Provided is a method for modulating an immune response which is not derived from alphavirus infection comprising administering to a subject in need thereof an effective amount of a composition comprising an alphavirus virus like particle.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: January 1, 2019
    Assignee: VLP Therapeutics, LLC
    Inventors: Wataru Akahata, Ryuji Ueno
  • Patent number: 10155930
    Abstract: The invention relates to the use of a virus, preferably an adenovirus, for producing a medicament. Said virus is replication-deficient in cells which do not contain YB-1 in the core and codes for an oncogene or oncogene product, especially an oncogene protein, which transactivates at least one viral gene, preferably an adenoviral gene, said gene being selected among the group comprising E1B55kDa, E4orf6, E4orf3, and E3ADP.
    Type: Grant
    Filed: April 28, 2010
    Date of Patent: December 18, 2018
    Inventor: Per Sonne Holm
  • Patent number: 10149901
    Abstract: Influenza vaccines include hemagglutinin from at least one influenza A virus strain and at least one influenza B virus strain. They also include an oil-in-water emulsion adjuvant with submicron oil droplets, comprising squalene. In some embodiments the hemagglutinin concentration is >12 ?g/ml per strain. In some embodiments the squalene concentration is <19 mg/ml. In some embodiments the vaccine is mercury-free. In some embodiments the vaccine has a unit dose volume between 0.2-0.3 mL. In some embodiments the squalene concentration is 9.75 mg/mL or 4.88 mg/mL. In some embodiments the vaccine includes antigens from two influenza A virus strains and two influenza B virus strains.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: December 11, 2018
    Assignee: Seqirus UK Limited
    Inventors: Mario Contorni, Derek O'Hagan, Nicola Groth
  • Patent number: 10137191
    Abstract: Compositions, vaccines and methods for inducing protective immunity against Human Immunodeficiency Virus (HIV) infection are described. Heterologous vaccine combinations of one or more viral expression vectors and an isolated antigenic polypeptide induced strong protective immunity against infections by one or multiple clades of HIV.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: November 27, 2018
    Assignees: Janssen Vaccines & Prevention B.V., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Dan Barouch, Johanna Schuitemaker, Maria Grazia Pau, Danielle Van Manen, Frank Tomaka, Jennifer Anne Hendriks
  • Patent number: 10130701
    Abstract: The present invention provides a live, attenuated coronavirus comprising a variant replicase gene encoding polyproteins comprising a mutation in one or more of non-structural protein(s) (nsp)-10, nsp-14, nsp-15 or nsp-16. The coronavirus may be used as a vaccine for treating and/or preventing a disease, such as infectious bronchitis, in a subject.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: November 20, 2018
    Assignee: THE PIRBRIGHT INSTITUTE
    Inventors: Erica Bickerton, Sarah Keep, Paul Britton
  • Patent number: 10130696
    Abstract: The present invention relates to vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to methods of conferring protective immunity to Norovirus infections in a human subject.
    Type: Grant
    Filed: September 18, 2008
    Date of Patent: November 20, 2018
    Assignee: TAKEDA VACCINES, INC.
    Inventors: Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, William Tino